BIVDA Press Releases

Jun 02, 2021
BIVDA offers industry support to Government for COP26 climate goals BIVDA, the trade association for in-vitro diagnostic companies, has written to the President of COP26, Alok Sharma MP, to offer the support of the industry for the forthcoming COP26 summit in Glasgow. BIVDA and its members have been at the forefront of our response to the pandemic, working closely with colleagues at NHS England the Department for Health and Social Care during this challenging period. As part of this cr...
Read More
May 26, 2021
Press Release                                                                                 &...
Read More
May 21, 2021
The British In-Vitro Diagnostic Association (BIVDA) has launched the first in a series of strategy papers, which will assess what the UK IVD industry needs to grow and thrive in the future. The first of these papers ’Emerging from the Pandemic – An Industry View’ examines what needs to be done to lock in our progress in developing systems to cope with infectious diseases. The outbreak of SARS-CoV-2 first detected in China in December 2019 has been challenging for countries...
Read More
May 13, 2021
IPSWICH, MA (May 10th, 2021) — New England Biolabs, Inc. (NEB®), a leading supplier of life science reagents, today announces that it has entered into an agreement to acquire Fluorogenics Limited (FGL), a lyophilization R&D service company based in the UK. Under the terms of the agreement, FGL will become a wholly-owned subsidiary of NEB. With the point-of-care market becoming more focused on the development of robust, accurate and cost-effective diagnostic tests for use outsi...
Read More
May 11, 2021
BIVDA Chief Executive Doris-Ann Williams and Chief Operating Officer Helen Dent have commented on the publication of the Health and Care Bill in today’s Queen’s Speech.  Commenting on plans to promote integrated care in the health service, Doris-Ann said; “The new White Paper offers an opportunity to promote joint working and collaboration in the NHS across different teams, department and disciplines. As part of these reforms, we want to see greater use of IVDs in pri...
Read More
May 07, 2021
BIVDA commentary on proposed validation of COVID Antigen tests for sale in the private sector7th May 2021 After careful consideration, BIVDA believes that setting up a separate validation process sets both an unwarranted precedent for the industry and undermines the regulatory system. Our position is that changes to the existing regulatory regime could achieve what the validation policy is trying to do, more effectively and without creating a two-layer system – a view in which we are ...
Read More
Apr 26, 2021
FluoretiQ Ltd. today announced the appointment of Mr Kasra Saeb-Parsy Consultant Urologist with Cambridge (UK) University Hospitals NHS Foundation Trust as their Chief Medical Officer. Mr. Saeb-Parsy will oversee and lead all clinical development, regulatory and medical affairs strategies and activities of the Company."I am delighted to welcome Kasra as our Chief Medical Officer at this key stage of our company growth as we approach clinical studies and regulatory approval in the UK and USA...
Read More
Apr 19, 2021
BIVDA welcomes NICE Five Year Plan BIVDA, the trade association for British IVD companies,  has welcomed the publication of NICE’s five year strategy document. The document runs from 2021 to 2026 and is designed to ensure the organisation remains “excellent”, more dynamic and more collaborative in their work. According to NICE,  the plan puts science and evidence at the heart of health and care decision making, while keeping ahead of the challenges of a rapidly c...
Read More
Apr 07, 2021
BIVDA, the trade association for British in-vitro diagnostic companies, has welcomed the launch of the ‘Medicines and Diagnostics Manufacturing Transformation Fund’ which is now open for applications. The new fund of £20 million is dedicated to expanding the manufacturing capacity of the life sciences industry.  The fund is open to manufacturers of human licensed medicines, medical diagnostics and medical devices, and projects must have a minimum total size of 8M, wit...
Read More
Apr 01, 2021
BIVDA launches the Don’t Wait;Act Testing Campaign For Immediate Release  -- BIVDA, the trade association for British in-vitro diagnostic companies, has launched its new Don’t Wait;Act campaign to re-start testing for non-COVID health issues today. Routine care and health screening for diseases such as cancers, heart disease and diabetes have either experienced long pauses or drops in take-ups from members of the public during the COVID-19 pandemic. As a result, t...
Read More
Page 2 of 12 [2]